FULC Insider Trading

Insider Ownership Percentage: 4.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $59,071.84

Fulcrum Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Fulcrum Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M-$10M$0$10M$20MTotal Insider BuyingTotal Insider Selling

Fulcrum Therapeutics Share Price & Price History

Current Price: $4.00
Price Change: Price Increase of +0.04 (1.01%)
As of 01/21/2025 05:00 PM ET

This chart shows the closing price history over time for FULC up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MarAprMayJunJulAugSepOctNovDecJan$4.00Closing price on 01/21/25:

SEC Filings (Institutional Ownership Changes) for Fulcrum Therapeutics (NASDAQ:FULC)

89.83% of Fulcrum Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at FULC by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$10ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$20M$0$20MTotal InflowsTotal Outflows
Fulcrum Therapeutics logo
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Read More on Fulcrum Therapeutics

Today's Range

Now: $4.00
Low: $3.95
High: $4.07

50 Day Range

MA: $4.06
Low: $2.97
High: $5.08

52 Week Range

Now: $4.00
Low: $2.86
High: $13.70

Volume

867,973 shs

Average Volume

628,414 shs

Market Capitalization

$215.76 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.06

Who are the company insiders with the largest holdings of Fulcrum Therapeutics?

Fulcrum Therapeutics' top insider investors include:
  1. Greg Tourangeau (Insider)
  2. Greg Tourangeau (VP)
Learn More about top insider investors at Fulcrum Therapeutics.

Who are the major institutional investors of Fulcrum Therapeutics?

Fulcrum Therapeutics' top institutional shareholders include:
  1. SG Americas Securities LLC — 0.06%
Learn More about top institutional investors of Fulcrum Therapeutics stock.

Which major investors are selling Fulcrum Therapeutics stock?

Within the previous quarter, FULC stock was sold by these institutional investors:
  1. SG Americas Securities LLC
In the previous year, company insiders that have sold Fulcrum Therapeutics company stock include:
  1. Greg Tourangeau (Insider)
  2. Greg Tourangeau (VP)
Learn More investors selling Fulcrum Therapeutics stock.